If you experience any of the above conditions or suspect that you might have symptoms that indicate them, seek urgent attention from a healthcare provider
According to a recent study, approximately 50% of pet owners stated they received no demonstration on medication administration, while one-third encountered difficulties, primarily due to resistant pets (3)
In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated adult patients showed cross-reactivity to native GIP or native GLP-1, respectively
Still in clinical development, early studies suggest it may deliver even greater weight loss than current drugs, but it is not yet available for general use
This is the pharmacological basis for CagriSema : in REDEFINE 1, the combination produced 20.4% mean weight loss versus 11.8% for cagrilintide alone and 14.9% for semaglutide alone